临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1228013-15-7

CC-115

CAS号:1228013-15-7
分子式: C16H16N8O 分子量: 336.35
产品形式: free base
研发状态: Completed
研发用途: Glioblastoma Multiforme; Squamous Cell Carcinoma of Head and Neck; Prostate Cancer; Ewing''s Osteosarcoma; Chronic Lymphocytic Leukemia; Neoplasm Metastasis
研究机构: Celgene
研发日期: April 25 2011
研发阶段: Phase 1
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR) with IC50 values of 0.013 μM and 0.021 μM, respectively. It has potential antineoplastic activity.

CAS: 1227633-49-9

StemRegenin 1 (SR1)

中文名称:StemRegenin1抑制剂
CAS号:1227633-49-9
分子式: C24H23N5OS 分子量: 429.54
产品形式: free base
研发状态: Completed
研发用途: Psoriasis
研究机构: Galderma R&D
研发日期: Sep-08
研发阶段: Phase 2
StemRegenin 1 (SR1) is an aryl hydrocarbon receptor (AhR) inhibitor with IC50 of 127 nM in a cell-free assay.

CAS: 1227163-84-9

AZD3839

中文名称:(S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺
CAS号:1227163-84-9
分子式: C24H16F3N5 分子量: 431.41
产品形式: free base
研发状态: Completed
研发用途: Alzheimer''s Disease; Safety; Tolerability; Blood Concentration; Healthy Volunteers
研究机构: AstraZeneca
研发日期: Jun-11
研发阶段: Phase 1
AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

CAS: 1227158-85-1

BAY 87-2243

中文名称:1-环丙基-4-[4-[[5-甲基-3-[3-[4-(三氟甲氧基)苯基]-1,2,4-恶二唑-5-基]-1H-吡唑-1-基]甲基]-2-吡啶基]哌嗪
CAS号:1227158-85-1
分子式: C26H26F3N7O2 分子量: 525.53
产品形式: Free Base
研发状态: Terminated
研发用途: Neoplasms
研究机构: Bayer
研发日期: Apr-11
研发阶段: Phase 1
BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. BAY 87-2243 inhibits mitochondrial complex I activity, thus triggering a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis. BAY 87-2243 exerts antitumor activity. Phase 1.

CAS: 1226781-44-7

Omarigliptin (MK-3102)

中文名称:奥格列汀
CAS号:1226781-44-7
分子式: C17H20F2N4O3S 分子量: 398.43
产品形式: free base
研发状态: Completed
研发用途: Type 2 Diabetes Mellitus
研究机构: Merck Sharp & Dohme LLC
研发日期: October 17 2016
研发阶段: Phase 4
Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).

CAS: 122647-32-9

Ibutilide Fumarate

中文名称:富马酸伊布利特
CAS号:122647-32-9
分子式: (C20H36N2O3S)2.C4H4O4 分子量: 885.23
产品形式: Fumarate
研发状态: Active not recruiting
研发用途: Long QT Syndrome; Abnormalities Drug-Induced
研究机构: Indiana University; American Heart Association; Purdue University
研发日期: March 26 2019
研发阶段: Phase 4
Ibutilide Fumarate (U-70226E,Corvert Fumarate) is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm by induction of slow inward sodium current, which prolongs action potential and refractory period of myocardial cells.